BeyondSpring (NASDAQ:BYSI – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.52, FiscalAI reports.
BeyondSpring Stock Performance
Shares of BeyondSpring stock opened at $0.84 on Friday. BeyondSpring has a 52-week low of $0.73 and a 52-week high of $2.44. The company has a fifty day moving average of $1.38 and a 200-day moving average of $1.49. The stock has a market capitalization of $34.50 million, a price-to-earnings ratio of -5.99 and a beta of 0.48.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of BeyondSpring in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.
Institutional Trading of BeyondSpring
A hedge fund recently raised its position in BeyondSpring stock. Geode Capital Management LLC grew its stake in shares of BeyondSpring Inc. (NASDAQ:BYSI – Free Report) by 16.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 368,682 shares of the company’s stock after buying an additional 53,198 shares during the quarter. Geode Capital Management LLC owned 0.91% of BeyondSpring worth $601,000 at the end of the most recent quarter. Institutional investors own 40.29% of the company’s stock.
BeyondSpring Company Profile
BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.
The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.
Read More
- Five stocks we like better than BeyondSpring
- AirJoule Technologies: Short Squeeze Setup Amid Rising Risks
- MarketBeat Week in Review – 08/10 – 08/14
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
